A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Eligible for screening study DCP 001
BN011 is reopened to accrual, effective January 13, 2026.
